First Time Loading...

Aridis Pharmaceuticals Inc
NASDAQ:ARDS

Watchlist Manager
Aridis Pharmaceuticals Inc Logo
Aridis Pharmaceuticals Inc
NASDAQ:ARDS
Watchlist
Price: 0.0747 USD 0.81% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

ARDS doesn't have a meaningful market cap.

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. [ Read More ]

The intrinsic value of one ARDS stock under the Base Case scenario is 10.0568 USD. Compared to the current market price of 0.0747 USD, Aridis Pharmaceuticals Inc is Undervalued by 99%.

Key Points:
ARDS Intrinsic Value
Base Case
10.0568 USD
Undervaluation 99%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

Financials

Balance Sheet Decomposition
Aridis Pharmaceuticals Inc

Current Assets 4.1m
Cash & Short-Term Investments 35k
Receivables 517k
Other Current Assets 3.6m
Non-Current Assets 2.4m
PP&E 1.6m
Intangibles 13k
Other Non-Current Assets 827k
Current Liabilities 17.5m
Accounts Payable 8.8m
Accrued Liabilities 8.3m
Other Current Liabilities 395k
Non-Current Liabilities 854k
Other Non-Current Liabilities 854k
Efficiency

Earnings Waterfall
Aridis Pharmaceuticals Inc

Revenue
22.4m USD
Operating Expenses
-23.2m USD
Operating Income
-883k USD
Other Expenses
-259k USD
Net Income
-1.1m USD

Free Cash Flow Analysis
Aridis Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ARDS Profitability Score
Profitability Due Diligence

Aridis Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional Revenue Growth Forecast
Exceptional ROIC
Exceptional 1-Year Revenue Growth
47/100
Profitability
Score

Aridis Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

ARDS Solvency Score
Solvency Due Diligence

Aridis Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
37/100
Solvency
Score

Aridis Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARDS Price Targets Summary
Aridis Pharmaceuticals Inc

There are no price targets for ARDS.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ARDS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ARDS Price
Aridis Pharmaceuticals Inc

1M 1M
-3%
6M 6M
-17%
1Y 1Y
-81%
3Y 3Y
-99%
5Y 5Y
-99%
10Y 10Y
-99%
Annual Price Range
0.0747
52w Low
0.06
52w High
0.4
Price Metrics
Average Annual Return -30.19%
Standard Deviation of Annual Returns 43.63%
Max Drawdown -100%
Shares Statistics
Market Capitalization 3.3m USD
Shares Outstanding 44 574 000
Percentage of Shares Shorted 6.8%

ARDS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Aridis Pharmaceuticals Inc Logo
Aridis Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.3m USD

Dividend Yield

0%

Description

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. The company is headquartered in Los Gatos, California and currently employs 34 full-time employees. The company went IPO on 2018-08-14. The firm is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The firm's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The firm's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.

Contact

CALIFORNIA
Los Gatos
983 University Avenue, Bldg. B
+14083851742.0
https://aridispharma.com

IPO

2018-08-14

Employees

34

Officers

Founder & Executive Chairman
Dr. Eric J. Patzer Ph.D.
Founder, CEO, Chief Scientific Officer & Director
Dr. Vu L. Truong Ph.D.
Chief Medical Officer
Dr. Hasan Jafri M.D.
Vice President of Finance
Ms. Tamara S. Allen
Acting General Counsel
Mr. Jeffrey J. Fessler Esq., J.D.

See Also

Discover More